Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who have been diagnosed with T-cell large granular lymphocytic leukemia (T-LGLL), a rare type of blood cancer
• People who meet at least one of the following reasons for needing treatment: low red blood cell levels or dependence on blood transfusions; very low white blood cell counts or frequent infections due to low white blood cell counts; an enlarged spleen that is growing or very large; an autoimmune disease (such as rheumatoid arthritis or autoimmune thyroid disease) that also requires treatment; or severe symptoms such as significant weight loss, drenching night sweats, or persistent fever
• People whose condition did not respond to, or who could not tolerate, a first course of standard treatment
• People who are well enough to carry out basic daily activities (based on a standard medical scoring system, this means scoring 0, 1, or 2 on the ECOG scale — confirm with trial site)
• People whose life expectancy is at least 6 months
• People who are willing and able to follow the study requirements and who have signed a written consent form

Who may not be able to join:

• People who have a history of other blood or lymph node cancers
• People who have had a malignant (cancerous) tumour within the past 5 years — exceptions may apply for certain fully cured, low-risk skin cancers or similarly treated early-stage cancers (confirm with trial site)
• People who have previously had an organ transplant or a stem cell transplant
• People who have had an active infection in the 2 weeks before starting the trial medication
• People who have hepatitis B, hepatitis C, HIV, or any other ongoing infection that requires treatment
• People with a history of a weakened immune system or a condition they were born with that affects the immune system
• People with serious or uncontrolled health conditions, including significant heart disease, high blood pressure that cannot be controlled, major metabolic disorders, or conditions that seriously affect the stomach or digestive system
• People whose liver function tests (specifically ALT and AST levels) are more than 2.5 times higher than the normal range, confirmed on two separate tests at least one week apart
• People with significantly reduced kidney function (a creatinine clearance measurement below 30 ml/min — confirm with trial site)
• People with a history of a mental illness
• People with a history of certain lung conditions, including pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation-related lung damage, drug-related lung damage, or severely reduced lung function
• People who have received a live (attenuated) vaccine within 4 weeks before joining the trial
• People who have taken part in another clinical trial within 4 weeks before the start of this trial
• People who have a known allergy to Linperlisib or any of its ingredients
• People who are pregnant or breastfeeding
• People whom the trial doctor considers unsuitable for the study for other medical reasons

Important: Always verify eligibility with the trial site directly before applying.